UNSPSC 51385405: Cinchophen piperazine

This classification denotes a nonsteroidal antiinflammatory drug C16H11NO2.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O65C9QHG6D, chemically known as 4-quinolinecarboxylic acid, 2-phenyl-, compd. with piperazine (1:1), but more generally known as cinchophen piperazine, which bears US NIH Compound Identifier 71300650. European Medicines Agency schedules Cinchophen piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01308MIG.

Most nations, for tariff and trade purposes, schedule cinchophen piperazine under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN PIPERAZINE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2CC(C3CCCCC3N2)C(=O)O.C1CNCCN1.

UNSPSC 51385405 Cinchophen piperazine is a Commodity code that does not align with recent state and local procurement activity. The three most recent opportunities posted under this code—a Seminole County naloxone and drug deactivation systems procurement, a Texas Health and Human Services Commission therapeutic pharmacy initiative RFI, and a Minnesota Multistate Cooperative Purchasing Alliance generic pharmaceuticals RFP—involve naloxone delivery, direct-to-manufacturer prescription programs, and broad-based generic pharmaceutical and OTC product supply contracts respectively. None of these solicitations involve cinchophen piperazine or related compounds. The code appears to capture a narrow pharmaceutical ingredient or active pharmaceutical ingredient that state and local governments do not actively procure through open competition, or the recent opportunities were mislabeled at the UNSPSC level.

State and local procurement bodies posting under this code include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota MMCAP, serving participating states including Oregon). The most recent opportunities posted in 2026 reflect broader pharmaceutical procurement strategies—naloxone kits for community health initiatives via IFB, market intelligence gathering on direct-to-manufacturer prescription fulfillment via RFI, and statewide generic pharmaceutical supply via RFP—but none target the specific chemical or therapeutic category this code nominally describes. No actionable procurement signal exists for cinchophen piperazine specifically under this code as of July 2026.